¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"gene flow"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • complementary gene
    º¸Á·À¯ÀüÀÚ, »óÈ£º¸ÃæÀ¯ÀüÀÚ
  • control gene
    Á¦¾îÀ¯ÀüÀÚ
  • cooperating gene
    Çùµ¿À¯ÀüÀÚ
  • catabolite (gene) activator protein
    ºÐÇØ´ë»ç»ê¹°(À¯ÀüÀÚ)Ȱ¼º´Ü¹éÁú
  • calcitonin gene-related peptide
    Ä®½ÃÅä´ÑÀ¯ÀüÀÚ°ü·ÃÆéƼµå
  • candidate gene
    Èĺ¸À¯ÀüÀÚ
  • duplicate gene
    º¹»çÀ¯ÀüÀÚ
  • determinant gene
    °áÁ¤À¯ÀüÀÚ
  • dominant gene
    ¿ì¼ºÀ¯ÀüÀÚ
  • gene
    À¯ÀüÀÚ
  • gene amplification
    À¯ÀüÀÚÁõÆø
  • gene analysis
    À¯ÀüÀںм®
  • gene cloning
    À¯ÀüÀÚŬ·Î´×, À¯ÀüÀÚº¹Á¦
  • gene conversion
    À¯ÀüÀÚÀüȯ
  • gene defect
    À¯ÀüÀÚ°á¼Õ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • blood flow meter
    Ç÷·ù°è
  • blood flow rate
    Ç÷·ù·®, Ç÷·ù¼Óµµ
  • blood flow velocity
    ÇÇÈ帧¼Óµµ, Ç÷·ù¼Óµµ
  • bulk flow
    µ¢ÀÌÈ帧, ¿ëÀûÈ帧
  • cerebrospinal fluid flow void sign
    ³úô¼ö¾×È帧¼Ò½Ç¡ÈÄ
  • co-current flow
    ¹Ù¸¥È帧, Á¤È帧
  • color flow mapping
    »öÇ÷·ùÁöµµÈ­
  • continuous-flow resectoscope
    Áö¼Ó°ü·ùÀýÁ¦°æ
  • counter flow
    ¸ÂÈ帧
  • flow chart
    È帧µµ, ¼ø¼­µµ
  • flow compensation
    È帧º¸»ó
  • flow cytometer
    È帧¼¼Æ÷ÃøÁ¤±â
  • flow cytometry
    È帧¼¼Æ÷ÃøÁ¤
  • flow volume curve
    À¯·®¿ë·®°î¼±
  • laminar flow cabinet
    ±â·ù½Ä¹«±Õ½ÇÇè´ë
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • gene, mutator
    º¯ÀÌÀ¯¹ßÀ¯ÀüÀÚ
  • gene, operator
    ÀÛµ¿À¯ÀüÀÚ
  • gene, regulatory
    Á¶ÀýÀ¯ÀüÀÚ
  • gene, repressor
    ¾ïÁ¦À¯ÀüÀÚ
  • gene, structural
    ±¸Á¶À¯ÀüÀÚ
  • gene, suppressor
    ¹ßÇö¾ïÁ¦À¯ÀüÀÚ
  • histocompatibility gene
    Á¶Á÷ÀûÇÕ¼º À¯ÀüÀÚ
  • histocompatibility gene
    Á¶Á÷ÀûÇÕÀ¯ÀüÀÚ.
  • immediate early gene
    Á¶±â ¹ßÇö À¯ÀüÀÚ
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ.
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • immunoglobulin (Ig) gene
    ¸é¿ª±Û·ÎºÒ¸° À¯ÀüÀÚ
  • immunoglobulin gene
    ¸é¿ª±Û·ÎºÒ¸°À¯ÀüÀÎÀÚ
  • ras gene
    ras À¯ÀüÀÚ(¡­ë¶îîí­)
  • rb gene
    Rb À¯ÀüÀÚ(¡­ë¶îîí­)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • gene recombination
    À¯ÀüÀÚÀçÁ¶ÇÕ
  • gene redundancy
    À¯ÀüÀÚÁߺ¹, À¯ÀüÀÚ¿©À¯
  • gene regulation
    À¯ÀüÀÚÁ¶Àý(ðàï½).
  • gene regulation
    À¯ÀüÀÚÁ¶Àý.
  • gene replacement
    À¯ÀüÀÚ±³È¯
  • gene segment
    À¯ÀüÀÚºÐÀý
  • gene therapy
    À¯ÀüÀÚÄ¡·á
  • gene tracking
    À¯ÀüÀÚÃßÀû
  • gene transfection
    À¯ÀüÀÚÀü´Þ°¨¿°
  • gene transfer
    À¯ÀüÀÚÀü´Þ(îîÓ¹).
  • gene transfer
    À¯ÀüÀÚÀü´Þ.
  • gene translocation
    À¯ÀüÀÚÀüÀ§
  • gene, Is
    IsÀ¯ÀüÀÚ
  • gene, histocompatibility
    Á¶Á÷ÀûÇÕ¼º À¯ÀüÀÚ
  • gene, mutator
    º¯ÀÌÀ¯¹ßÀ¯ÀüÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • gene pair
    À¯ÀüÀÚ ½Ö(ë¶îîí­äª)
  • gene pool
    À¯ÀüÀÚ(ë¶îîí­) Ç®
  • gene product
    À¯ÀüÀÚ(ë¶îîí­) »ê¹°
  • gene reduncdancy
    À¯ÀüÀÚ Áߺ¹(ë¶îîí­ñìÜÜ)
  • gene reiteration
    À¯ÀüÀÚ Áߺ¹(ë¶îîí­ñìÜÜ)
  • gene repetition
    À¯ÀüÀÚ ¹Ýº¹(ë¶îîí­ÚãÜÖ)
  • gene splicing
    À¯ÀüÀÚ(ë¶îîí­) ½ºÇöóÀ̽Ì
  • gene substitution
    À¯ÀüÀÚ Ä¡È¯(ë¶îîí­öÇüµ)
  • gene synthesis
    À¯Àü»ç ÇÕ¼º(ë¶îîí­ùêà÷)
  • gene therapy
    À¯ÀüÀÚ Ä¡·á(ë¶îîí­ö½Öû)
  • gene transfection
    À¯ÀüÀÚ ÀÌÀÔ(ë¶îîíºì¹ìý)
  • gene walking
    À¯ÀüÀÚ(ë¶îîí­) °È±â
  • hemizygous gene
    ¹ÝÁ¢ÇÕ À¯ÀüÀÚ(ÚâïÈùêë¶îîí­)
  • hgh-mutability gene
    °íº¯ÀÌ´É À¯ÀüÀÚ(ÍÔܨì¶Òöë¶îîí­)
  • histocompatibility gene
    Á¶Á÷ ÀûÇÕ¼º À¯ÀüÀÚ(ðÚòÄîêùêàõë¶îîí­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
ARGS antitrypsin-related gene sequence
CAP camptodactyly-arthropathy-pericarditis [syndrome]; Canada Assistance Plan; capsule; captopril; catab...
CGA catabolite gene activator; color graphics adapter
CGP N-carbobenzoxy-glycyl-L-phenylalanine; chorionic growth hormone-prolactin; choline glycerophosphatid...
CGRP calcitonin gene-related peptide
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
ESAG expression site-associated gene
FMR1 Fragile X Mental Retardation gene 1
g32P Gene 32 protein
GDEPT Gene directed enzyme prodrug therapy
GP Gene products
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • renal plasma flow
    ½Å Ç÷Àå·ù, ½Å Ç÷Àå·ù·®
  • salivary flow rate
    Ÿ¾× ºÐºñÀ²
  • stimulated parotid flow rate
    Àڱؼº ÀÌÇϼ± ºÐºñÀ²
  • streamline flow
    À¯¼±Çü È帧
  • tear flow
    ´«¹° È帧, ´©¾×·ù
  • to and fro flow
    ÀüÈÄ À¯µ¿
  • total flow
    ÃÑ À¯·®, Àüü À¯·®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
gene disorder Hereditary disorder caused by a mutant allele of a single gene (e.g., Duchenne muscular dystrophy, retinoblastoma, sickle cell disease).
Compare polygenic disorders.
(05 Mar 2000)
gene disruption Use of both in vitro and in vivo recombination to substitute an easily selected mutant gene for a wild-type gene.
(09 Oct 1997)
gene divergence The difference (expressed as a percentage) in the nucleotide sequencesbetween two related genes that developed from the same ancestral gene.
(09 Oct 1997)
gene dosage <molecular biology> Number of copies of a particular gene locus in the genome, in most cases either one or two.
(18 Nov 1997)
gene dosage compensation The putative mechanism that adjusts the X-linked phenotypes of males and females to compensate for the haploid state in males and the diploid state in females. It is now largely ascribed to lyonization which compensates the mean of the dose but not its variance, which is greater in females.
(05 Mar 2000)
gene dosage effect In codominant alleles, the more or less linear relationship between the phenotypic value and the number of genes of one type substituted by another type.
(05 Mar 2000)
gene duplication <molecular biology> A class of DNA rearrangement that generates a supernumerary copy of a gene in the genome. This would allow each gene to evolve independently to produce distinct functions. Such a set of evolutionarily related genes can be called a gene family.
(18 Nov 1997)
gene, evolutionarily conserved A gene that has remained essentially unchanged throughout evolution. Conservation of a gene indicates that it is unique and essential. There is not an extra copy of that gene with which evolution can tinker. And changes in the gene are likely to be lethal.
(12 Dec 1998)
gene expression <molecular biology> The full use of the information in a gene via transcription and translation leading to production of a protein and hence the appearance of the phenotype determined by that gene. Gene expression is assumed to be controlled at various points in the sequence leading to protein synthesis and this control is thought to be the major determinant of cellular differentiation in eukaryotes.
(18 Nov 1997)
gene expression regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action at the level of transcription or translation. These processes include gene activation and genetic induction.
(12 Dec 1998)
gene expression regulation, archaeal Any of the processes by which cytoplasmic or intercellular factors influence the differential control of gene action in archaea.
(12 Dec 1998)
gene expression regulation, bacterial Any of the processes by which cytoplasmic or intercellular factors influence the differential control of gene action in bacteria.
(12 Dec 1998)
gene expression regulation, developmental Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action during the developmental stages of an organism.
(12 Dec 1998)
gene expression regulation, enzymologic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in enzyme synthesis.
(12 Dec 1998)
gene expression regulation, fungal Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in fungi.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á